Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.

Cruz LJ, Tacken PJ, van der Schoot JMS, Rueda F, Torensma R, Figdor CG.

Molecules. 2019 May 12;24(9). pii: E1825. doi: 10.3390/molecules24091825.

2.

Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity.

Cruz LJ, Tacken PJ, Eich C, Rueda F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2017 Mar;12(5):491-510. doi: 10.2217/nnm-2016-0295. Epub 2017 Feb 9.

PMID:
28181470
3.

Tracking targeted bimodal nanovaccines: immune responses and routing in cells, tissue, and whole organism.

Cruz LJ, Tacken PJ, Zeelenberg IS, Srinivas M, Bonetto F, Weigelin B, Eich C, de Vries IJ, Figdor CG.

Mol Pharm. 2014 Dec 1;11(12):4299-313. doi: 10.1021/mp400717r. Epub 2014 Oct 24.

PMID:
25290882
4.

Targeting dendritic cells--why bother?

Kreutz M, Tacken PJ, Figdor CG.

Blood. 2013 Apr 11;121(15):2836-44. doi: 10.1182/blood-2012-09-452078. Epub 2013 Feb 6.

PMID:
23390195
5.

Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.

Cruz LJ, Rueda F, Tacken P, Albericio F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2012 Oct;7(10):1591-610. doi: 10.2217/nnm.12.131. Review.

PMID:
23148541
6.

Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking.

Tacken PJ, Ter Huurne M, Torensma R, Figdor CG.

Eur J Immunol. 2012 Aug;42(8):1989-98. doi: 10.1002/eji.201142258.

7.

Targeting nanoparticles to dendritic cells for immunotherapy.

Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG.

Methods Enzymol. 2012;509:143-63. doi: 10.1016/B978-0-12-391858-1.00008-3. Review.

PMID:
22568905
8.

Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.

Aarntzen EH, de Vries IJ, Göertz JH, Beldhuis-Valkis M, Brouwers HM, van de Rakt MW, van der Molen RG, Punt CJ, Adema GJ, Tacken PJ, Joosten I, Jacobs JF.

Cancer Immunol Immunother. 2012 Nov;61(11):2003-11. doi: 10.1007/s00262-012-1263-z. Epub 2012 Apr 21.

9.

Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.

Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG.

Biomaterials. 2012 Jun;33(16):4229-39. doi: 10.1016/j.biomaterials.2012.02.036. Epub 2012 Mar 10.

PMID:
22410170
10.

The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.

Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ.

Blood. 2012 Mar 8;119(10):2284-92. doi: 10.1182/blood-2011-08-373944. Epub 2012 Jan 10.

PMID:
22234694
11.

Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity.

Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, Lambeck AJ, Figdor CG.

Blood. 2011 Dec 22;118(26):6836-44. doi: 10.1182/blood-2011-07-367615. Epub 2011 Oct 3.

PMID:
21967977
12.

Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation.

Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, Figdor CG, Cambi A.

Blood. 2011 Oct 13;118(15):4111-9. doi: 10.1182/blood-2011-04-346957. Epub 2011 Aug 22.

PMID:
21860028
13.

The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.

Cruz LJ, Tacken PJ, Fokkink R, Figdor CG.

Biomaterials. 2011 Oct;32(28):6791-803. doi: 10.1016/j.biomaterials.2011.04.082. Epub 2011 Jul 2.

PMID:
21724247
14.

DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells.

Tel J, Benitez-Ribas D, Hoosemans S, Cambi A, Adema GJ, Figdor CG, Tacken PJ, de Vries IJ.

Eur J Immunol. 2011 Apr;41(4):1014-23. doi: 10.1002/eji.201040790. Epub 2011 Mar 17.

15.

Multimodal imaging of nanovaccine carriers targeted to human dendritic cells.

Cruz LJ, Tacken PJ, Bonetto F, Buschow SI, Croes HJ, Wijers M, de Vries IJ, Figdor CG.

Mol Pharm. 2011 Apr 4;8(2):520-31. doi: 10.1021/mp100356k. Epub 2011 Mar 16.

PMID:
21381651
16.

Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.

Tacken PJ, Figdor CG.

Semin Immunol. 2011 Feb;23(1):12-20. doi: 10.1016/j.smim.2011.01.001. Epub 2011 Jan 26. Review.

PMID:
21269839
17.

Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.

Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries IJ, Figdor CG.

J Immunol. 2010 Apr 15;184(8):4276-83. doi: 10.4049/jimmunol.0903286. Epub 2010 Mar 19.

18.

Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro.

Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG.

J Control Release. 2010 Jun 1;144(2):118-26. doi: 10.1016/j.jconrel.2010.02.013. Epub 2010 Feb 13.

PMID:
20156497
19.
20.

No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation.

Tacken PJ, Joosten B, Reddy A, Wu D, Eek A, Laverman P, Kretz-Rommel A, Adema GJ, Torensma R, Figdor CG.

J Immunol. 2008 Jun 1;180(11):7687-96.

21.

Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.

Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, Adema GJ.

Blood. 2008 Apr 15;111(8):4245-53. doi: 10.1182/blood-2007-03-081398. Epub 2008 Feb 7.

PMID:
18258799
22.

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Tacken PJ, de Vries IJ, Torensma R, Figdor CG.

Nat Rev Immunol. 2007 Oct;7(10):790-802. Review.

PMID:
17853902
23.

Relevance of DC-SIGN in DC-induced T cell proliferation.

Gijzen K, Tacken PJ, Zimmerman A, Joosten B, de Vries IJ, Figdor CG, Torensma R.

J Leukoc Biol. 2007 Mar;81(3):729-40. Epub 2006 Nov 29.

PMID:
17135574
24.

Targeting antigens to dendritic cells in vivo.

Tacken PJ, Torensma R, Figdor CG.

Immunobiology. 2006;211(6-8):599-608. Epub 2006 Jul 7. Review.

PMID:
16920498
25.
26.

Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses.

Dakappagari N, Maruyama T, Renshaw M, Tacken P, Figdor C, Torensma R, Wild MA, Wu D, Bowdish K, Kretz-Rommel A.

J Immunol. 2006 Jan 1;176(1):426-40.

27.

Respiratory innate immune proteins differentially modulate the neutrophil respiratory burst response to influenza A virus.

White MR, Crouch E, Vesona J, Tacken PJ, Batenburg JJ, Leth-Larsen R, Holmskov U, Hartshorn KL.

Am J Physiol Lung Cell Mol Physiol. 2005 Oct;289(4):L606-16. Epub 2005 Jun 10.

28.

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.

Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG.

Blood. 2005 Aug 15;106(4):1278-85. Epub 2005 May 5.

PMID:
15878980
29.

Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein.

Tacken PJ, Hartshorn KL, White MR, van Kooten C, van de Winkel JG, Reid KB, Batenburg JJ.

J Immunol. 2004 Apr 15;172(8):4934-40.

30.

VLDL receptor deficiency enhances intimal thickening after vascular injury but does not affect atherosclerotic lesion area.

Tacken PJ, Delsing DJ, Gijbels MJ, Quax PH, Havekes LM, Hofker MH, van Dijk KW.

Atherosclerosis. 2002 May;162(1):103-10.

PMID:
11947903
31.

Protection from obesity in mice lacking the VLDL receptor.

Goudriaan JR, Tacken PJ, Dahlmans VE, Gijbels MJ, van Dijk KW, Havekes LM, Jong MC.

Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1488-93.

PMID:
11557677
32.

Effective generation of very low density lipoprotein receptor transgenic mice by overlapping genomic DNA fragments: high testis expression and disturbed spermatogenesis.

Tacken PJ, van der Zee A, Beumer TL, Florijn RJ, Gijpels MJ, Havekes LM, Frants RR, van Dijk KW, Hofker MH.

Transgenic Res. 2001 Jun;10(3):211-21.

PMID:
11437278
33.

Living up to a name: the role of the VLDL receptor in lipid metabolism.

Tacken PJ, Hofker MH, Havekes LM, van Dijk KW.

Curr Opin Lipidol. 2001 Jun;12(3):275-9. Review.

PMID:
11353330
34.

LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice.

Tacken PJ, Teusink B, Jong MC, Harats D, Havekes LM, van Dijk KW, Hofker MH.

J Lipid Res. 2000 Dec;41(12):2055-62.

35.

Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.

Tacken PJ, Beer FD, Vark LC, Havekes LM, Hofker MH, Willems Van Dijk K.

Biochem J. 2000 Apr 15;347(Pt 2):357-61.

36.

Modulating effects of thyroid state on the induction of biotransformation enzymes by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Schuur AG, Tacken PJ, Visser TJ, Brouwer A.

Environ Toxicol Pharmacol. 1998 Jan;5(1):7-16.

PMID:
21781845

Supplemental Content

Loading ...
Support Center